Scienture Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $115.68M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 20, 2026 | After market close | $343.64K | $-0.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 22, 2026 | After market close | $56.33K | $-0.08 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | After market close | $2.20M | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 27, 2023 | After market close | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 7, 2022 | After market close | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Jul 25, 2022 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 9, 2022 | After market close | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 28, 2022 | After market close | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Oct 25, 2021 | After market close | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Jul 26, 2021 | After market close | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | Apr 26, 2021 | After market close | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Mar 29, 2021 | After market close | – | – | – |
Press releases
Announcements Scienture filed with the SEC
Holdings, Inc. Announces Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Holdings, Inc. Obtains $1.2 Million in Bridge Funding
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Listing notice · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Holdings, Inc. Announces Private Placement of $3 Million of 10% Secured Convertible Debentures as Initial Tranche of $12 Million Offering
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Health, Inc. Announces Name Change to Scienture Holdings, Inc.
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”
Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Health, Inc. Announces Special Cash Dividend
Other events · EX-99.1 to Form 8-K
Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
Listing notice · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Health, Inc. Announces Special Cash Dividend
Material agreement · Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Trxade health, Inc files its 3Q 10Q
Other events · EX-99.1 to Form 8-K
Announces Distribution Partnership with North America’s Leading Wholesale Distributor and Expanded Points of Retail Sales
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.
Regulation FD disclosure · EX-99.1 to Form 8-K
Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.
Material agreement · Acquisition or disposition completed · Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
HEALTH, Inc. Amends Definitive Merger
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Health, Inc.’s Board of Directors
Other events · EX-99.1 to Form 8-K
HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HEALTH Reports 16% Revenue Growth and Year End 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HEALTH Reports Third Quarter Gross Margin of 58% and Q3 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Health Announces Pricing of $1.8 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Advisory Board Member and Leading Pharmaceutical Industry
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Notice to TRxADE HEALTH Press Release
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A